Every trade that managers of Organigram Global Inc. disclose to SEDI is tracked on this page. The company sits in the Health Care sector. In the past year (23 October 2025 to 23 October 2026), 45 filings came from 9 insiders.
Both sides are active: 2 purchases worth €20k and 20 sales worth €248k, from 2 insiders and 7 insiders respectively. Sales outweigh purchases by €227k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €43k, sold by Goldenberg, Beena and made public on 24 October 2025. Those buying include 2 senior executives.
With 45 filings in twelve months, the company is more active than the median of 12 filings across the 2,471 companies we follow on the same exchange. Looking back to 2025, when coverage begins, insiders filed 3 purchases and 56 sales.
The last insider purchase was made public on 25 May 2026, 151 days ago. Typically, a trade is published a median of 3 days after it takes place. This delay matters because a trade only becomes useful information once it is public. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.
+4 other insiders
Analysts rate Organigram Global Inc. Buy (bullish), based on 5 analysts. Average price target: CA$2.92.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended September 2025 · cache
25 of 127 declarations
Organigram Global Inc. is a Canadian company focused on cannabis production. It is listed on the Toronto Stock Exchange under the symbol XTSE.
Purchases our model currently ranks for the recommendations list.
All recommendations